HIVEC for non-muscle-invasive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called HIVEC (a type of heated chemotherapy placed directly into the bladder) for people with non-muscle-invasive bladder cancer that is at medium or high risk of coming back. It aims to see if this approach can reduce the chance of cancer returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a type of bladder cancer called non-muscle-invasive urothelial carcinoma (cancer that hasn't spread into the muscle layer of the bladder wall).
- Your cancer is considered medium-risk or high-risk by your doctor.
- You are able to care for yourself (KPS score of 80 or higher) and expected to live more than 2.5 years.
- You have not had BCG, heat therapy, pelvic radiation, or certain other cancer treatments before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment called HIVEC, which delivers heated chemotherapy directly into the bladder. It's for people with a certain type of non-muscle-invasive bladder cancer that hasn't gotten better or has come back after BCG treatment, and who can't have or don't want bladder removal surgery.
This trial tests a new, precise way to use chemotherapy to remove low-risk, non-muscle-invasive bladder tumors before surgery. It may be an option for people with small, slow-growing tumors that haven't spread into the bladder muscle.
This trial tests an “oncolytic virus” treatment given into the bladder to fight high-grade non–muscle-invasive bladder cancer. It may help people whose bladder cancer did not respond to initial bladder prevention treatments, potentially delaying or avoiding major bladder surgery.
This trial checks whether a bladder scan and score (VI-RADS from MRI) can help doctors choose the right way to do a second look surgery for non-muscle-invasive bladder cancer. The goal is to reduce the chance of needing extra (“secondary”) resections while still catching important disease early.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.